These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 22849332

  • 1. Rationalization of paclitaxel insensitivity of yeast β-tubulin and human βIII-tubulin isotype using principal component analysis.
    Das L, Bhattacharya B, Basu G.
    BMC Res Notes; 2012 Aug 01; 5():395. PubMed ID: 22849332
    [Abstract] [Full Text] [Related]

  • 2. Novel mutations involving βI-, βIIA-, or βIVB-tubulin isotypes with functional resemblance to βIII-tubulin in breast cancer.
    Wang W, Zhang H, Wang X, Patterson J, Winter P, Graham K, Ghosh S, Lee JC, Katsetos CD, Mackey JR, Tuszynski JA, Wong GK, Ludueña RF.
    Protoplasma; 2017 May 01; 254(3):1163-1173. PubMed ID: 27943021
    [Abstract] [Full Text] [Related]

  • 3. Identification and characterization of an intermediate taxol binding site within microtubule nanopores and a mechanism for tubulin isotype binding selectivity.
    Freedman H, Huzil JT, Luchko T, Ludueña RF, Tuszynski JA.
    J Chem Inf Model; 2009 Feb 01; 49(2):424-36. PubMed ID: 19434843
    [Abstract] [Full Text] [Related]

  • 4. The role of beta-tubulin isotypes in resistance to antimitotic drugs.
    Burkhart CA, Kavallaris M, Band Horwitz S.
    Biochim Biophys Acta; 2001 Feb 01; 1471(2):O1-9. PubMed ID: 11342188
    [No Abstract] [Full Text] [Related]

  • 5. βII-tubulin and βIII-tubulin mediate sensitivity to peloruside A and laulimalide, but not paclitaxel or vinblastine, in human ovarian carcinoma cells.
    Kanakkanthara A, Northcote PT, Miller JH.
    Mol Cancer Ther; 2012 Feb 01; 11(2):393-404. PubMed ID: 22180309
    [Abstract] [Full Text] [Related]

  • 6. Mobility and Core-Protein Binding Patterns of Disordered C-Terminal Tails in β-Tubulin Isotypes.
    Laurin Y, Eyer J, Robert CH, Prevost C, Sacquin-Mora S.
    Biochemistry; 2017 Mar 28; 56(12):1746-1756. PubMed ID: 28290671
    [Abstract] [Full Text] [Related]

  • 7. Cloning and sequencing of human betaIII-tubulin cDNA: induction of betaIII isotype in human prostate carcinoma cells by acute exposure to antimicrotubule agents.
    Ranganathan S, Dexter DW, Benetatos CA, Hudes GR.
    Biochim Biophys Acta; 1998 Jan 21; 1395(2):237-45. PubMed ID: 9473684
    [Abstract] [Full Text] [Related]

  • 8. Mechanism of action of ixabepilone and its interactions with the βIII-tubulin isotype.
    Lopus M, Smiyun G, Miller H, Oroudjev E, Wilson L, Jordan MA.
    Cancer Chemother Pharmacol; 2015 Nov 21; 76(5):1013-24. PubMed ID: 26416565
    [Abstract] [Full Text] [Related]

  • 9. 2-(m-Azidobenzoyl)taxol binds differentially to distinct β-tubulin isotypes.
    Yang CH, Yap EH, Xiao H, Fiser A, Horwitz SB.
    Proc Natl Acad Sci U S A; 2016 Oct 04; 113(40):11294-11299. PubMed ID: 27651486
    [Abstract] [Full Text] [Related]

  • 10. Peloruside- and laulimalide-resistant human ovarian carcinoma cells have βI-tubulin mutations and altered expression of βII- and βIII-tubulin isotypes.
    Kanakkanthara A, Wilmes A, O'Brate A, Escuin D, Chan A, Gjyrezi A, Crawford J, Rawson P, Kivell B, Northcote PT, Hamel E, Giannakakou P, Miller JH.
    Mol Cancer Ther; 2011 Aug 04; 10(8):1419-29. PubMed ID: 21653684
    [Abstract] [Full Text] [Related]

  • 11. Modulation of endogenous beta-tubulin isotype expression as a result of human beta(III)cDNA transfection into prostate carcinoma cells.
    Ranganathan S, McCauley RA, Dexter DW, Hudes GR.
    Br J Cancer; 2001 Sep 01; 85(5):735-40. PubMed ID: 11531260
    [Abstract] [Full Text] [Related]

  • 12. Delineating the interaction of combretastatin A-4 with αβ tubulin isotypes present in drug resistant human lung carcinoma using a molecular modeling approach.
    Kumbhar BV, Bhandare VV, Panda D, Kunwar A.
    J Biomol Struct Dyn; 2020 Feb 01; 38(2):426-438. PubMed ID: 30831055
    [Abstract] [Full Text] [Related]

  • 13. The paclitaxel site in tubulin probed by site-directed mutagenesis of Saccharomyces cerevisiae beta-tubulin.
    Entwistle RA, Winefield RD, Foland TB, Lushington GH, Himes RH.
    FEBS Lett; 2008 Jul 09; 582(16):2467-70. PubMed ID: 18570892
    [Abstract] [Full Text] [Related]

  • 14. Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells.
    Ranganathan S, Benetatos CA, Colarusso PJ, Dexter DW, Hudes GR.
    Br J Cancer; 1998 Feb 09; 77(4):562-6. PubMed ID: 9484812
    [Abstract] [Full Text] [Related]

  • 15. Analysis of tubulin isotypes and mutations from taxol-resistant cells by combined isoelectrofocusing and mass spectrometry.
    Verdier-Pinard P, Wang F, Martello L, Burd B, Orr GA, Horwitz SB.
    Biochemistry; 2003 May 13; 42(18):5349-57. PubMed ID: 12731876
    [Abstract] [Full Text] [Related]

  • 16. Identification of betaIII- and betaIV-tubulin isotypes in cold-adapted microtubules from Atlantic cod (Gadus morhua): antibody mapping and cDNA sequencing.
    Modig C, Olsson PE, Barasoain I, de Ines C, Andreu JM, Roach MC, Ludueña RF, Wallin M.
    Cell Motil Cytoskeleton; 1999 May 13; 42(4):315-30. PubMed ID: 10223637
    [Abstract] [Full Text] [Related]

  • 17. Characterization of the colchicine binding site on avian tubulin isotype betaVI.
    Sharma S, Poliks B, Chiauzzi C, Ravindra R, Blanden AR, Bane S.
    Biochemistry; 2010 Apr 06; 49(13):2932-42. PubMed ID: 20178367
    [Abstract] [Full Text] [Related]

  • 18. BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability.
    Kamath K, Wilson L, Cabral F, Jordan MA.
    J Biol Chem; 2005 Apr 01; 280(13):12902-7. PubMed ID: 15695826
    [Abstract] [Full Text] [Related]

  • 19. Targeting an Old Foe for Cancer: A Molecular Dynamics Perspective to Unravel the Specific Binding Nature of 2-Methoxy Estradiol to Human β-Tubulin Isotypes.
    Kumari S, Sobhia ME.
    J Chem Inf Model; 2024 May 27; 64(10):4121-4133. PubMed ID: 38706255
    [Abstract] [Full Text] [Related]

  • 20. Resistance to the tubulin-binding agents in renal cell carcinoma: no mutations in the class I beta-tubulin gene but changes in tubulin isotype protein expression.
    Ferguson RE, Taylor C, Stanley A, Butler E, Joyce A, Harnden P, Patel PM, Selby PJ, Banks RE.
    Clin Cancer Res; 2005 May 01; 11(9):3439-45. PubMed ID: 15867246
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.